Milestone Pharmaceuticals (MIST) Cash & Current Investments (2018 - 2026)
Milestone Pharmaceuticals (MIST) posted Cash & Current Investments of $184.2 million for Q1 2026, up 73.86% on a QoQ basis from $106.0 million in Q4 2025, and up 1594.26% year-over-year from $10.9 million in Q1 2025.
Milestone Pharmaceuticals (MIST) Cash & Current Investments (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $184.2 million for Q1 2026.
- Quarterly Cash & Current Investments rose 1594.26% year-over-year to $184.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.2 million (up 1594.26% YoY) and the FY2025 annual result came in at $106.0 million, up 51.99% from the prior year.
- Cash & Current Investments was $184.2 million for Q1 2026 at Milestone Pharmaceuticals, up from $106.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $184.2 million in Q1 2026 and bottomed at $10.9 million in Q1 2025.
- A 5-year average of $88.5 million and a median of $79.4 million in 2024 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2025 — Cash & Current Investments slumped 86.3% — and 2026, when it soared 1594.26%.
- Milestone Pharmaceuticals' Cash & Current Investments stood at $64.5 million in 2022, then advanced by 2.21% to $66.0 million in 2023, then grew by 5.69% to $69.7 million in 2024, then surged by 51.99% to $106.0 million in 2025, then surged by 73.86% to $184.2 million in 2026.
- Business Quant data shows MIST's Cash & Current Investments at $184.2 million in Q1 2026, $106.0 million in Q4 2025, and $118.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Milestone Pharmaceuticals | 148.53 Mn | -35.69 Mn | - | 184.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184.22 Mn |
| Dec 31, 2025 | 105.96 Mn |
| Sep 30, 2025 | 118.50 Mn |
| Jun 30, 2025 | 43.42 Mn |
| Mar 31, 2025 | 10.87 Mn |
| Dec 31, 2024 | 69.71 Mn |
| Sep 30, 2024 | 63.62 Mn |
| Jun 30, 2024 | 69.99 Mn |
| Mar 31, 2024 | 79.35 Mn |
| Dec 31, 2023 | 65.96 Mn |
| Sep 30, 2023 | 141.57 Mn |
| Jun 30, 2023 | 87.59 Mn |
| Mar 31, 2023 | 128.00 Mn |
| Dec 31, 2022 | 64.54 Mn |
| Sep 30, 2022 | 77.23 Mn |
| Jun 30, 2022 | 86.24 Mn |
| Mar 31, 2022 | 108.20 Mn |
| Dec 31, 2021 | 114.14 Mn |
| Sep 30, 2021 | 141.40 Mn |
| Jun 30, 2021 | 173.80 Mn |